PROFILBARU.COM

Aliskiren/hydrochlorothiazide
Combination of
Aliskiren	Renin inhibitor
Hydrochlorothiazide	Diuretic
Clinical data
Trade names	Tekturna HCT, Rasilez HCT, others
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Aliskiren_hemifumarate_and_hydrochlorothiazide;
Routes of; administration	By mouth
ATC code	C09XA52 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
KEGG	D10289;

Aliskiren/hydrochlorothiazide, sold under the brand name Tekturna HCT among others, is a fixed-dose combination medication for the treatment of hypertension (high blood pressure).^[1]^[2]^[3]^[4] It contains aliskiren, a renin inhibitor, and hydrochlorothiazide, a diuretic.^[1]^[2] It is taken by mouth.^[1]

The most common side effect is diarrhea.^[2]

Aliskiren/hydrochlorothiazide was approved for medical use in the United States in January 2008,^[5] and for use in the European Union in January 2009.^[2]

Medical uses

Aliskiren/hydrochlorothiazide is indicated for the treatment of essential hypertension in adults.^[2]

References

^ ^a ^b ^c ^d "Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated". DailyMed. 7 January 2020. Retrieved 26 August 2020.
^ ^a ^b ^c ^d ^e ^f "Rasilez HCT EPAR". European Medicines Agency. 17 September 2018. Retrieved 27 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Chrysant SG (March 2008). "Aliskiren-hydrochlorothiazide combination for the treatment of hypertension". Expert Review of Cardiovascular Therapy. 6 (3): 305–14. doi:10.1586/14779072.6.3.305. PMID 18327992. S2CID 44410886.
^ Sureshkumar KK (2008). "Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy". Vascular Health and Risk Management. 4 (6): 1205–20. doi:10.2147/vhrm.s3364. PMC 2663460. PMID 19337534.
^
"Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 27 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 22-107: Summary review" (PDF). U.S. Food and Drug Administration (FDA).

External links

"Aliskiren hemifumarate mixture with hydrochlorothiazide". Drug Information Portal. U.S. National Library of Medicine.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[Tekturna_HCT_FDA_label-1] "Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated". DailyMed. 7 January 2020. Retrieved 26 August 2020.

[Rasilez_HCT_EPAR-2] ^ ^a ^b ^c ^d ^e ^f "Rasilez HCT EPAR". European Medicines Agency. 17 September 2018. Retrieved 27 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Chrysant_2008-3] Chrysant SG (March 2008). "Aliskiren-hydrochlorothiazide combination for the treatment of hypertension". Expert Review of Cardiovascular Therapy. 6 (3): 305–14. doi:10.1586/14779072.6.3.305. PMID 18327992. S2CID 44410886.

[Sureshkumar_2008-4] Sureshkumar KK (2008). "Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy". Vascular Health and Risk Management. 4 (6): 1205–20. doi:10.2147/vhrm.s3364. PMC 2663460. PMID 19337534.

[5] "Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 27 August 2020.
Lay summary in: "Center for Drug Evaluation and Research: Application Number: 22-107: Summary review" (PDF). U.S. Food and Drug Administration (FDA).

[6] Lay summary in: "Center for Drug Evaluation and Research: Application Number: 22-107: Summary review" (PDF). U.S. Food and Drug Administration (FDA).

[1]

[2]

[3]

[4]

[5]